Do analysts prefer PRTC or STOK?

Stoke Therapeutics has a consensus price target of $44.25, suggesting a potential upside of 72.72%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Stoke Therapeutics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Stoke Therapeutics 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.82

Which has better valuation & earnings, PRTC or STOK?

Stoke Therapeutics has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Stoke Therapeutics $27.59M 59.92 -$6.89M -$3.34 N/A

Do analysts prefer PRTC or NTLA?

Intellia Therapeutics has a consensus price target of $20.98, suggesting a potential upside of 71.11%. Given Intellia Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Intellia Therapeutics 4 Sell rating(s) 8 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.35

Which has stronger valuation and earnings, PRTC or NTLA?

PureTech Health has higher earnings, but lower revenue than Intellia Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Intellia Therapeutics $59.51M 28.87 -$412.69M -$3.36 N/A

Do analysts recommend PRTC or TSHA?

Taysha Gene Therapies has a consensus target price of $12.77, indicating a potential upside of 175.79%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts plainly believe Taysha Gene Therapies is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Taysha Gene Therapies 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has higher valuation and earnings, PRTC or TSHA?

Taysha Gene Therapies has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Taysha Gene Therapies $9.77M 154.41 -$109M -$0.42 N/A

Is PRTC or TSHA more profitable?

PureTech Health's return on equity of 0.00% beat Taysha Gene Therapies' return on equity. Company Net Margins Return on Equity Return on Assets PureTech Health N/A N/A N/A Taysha Gene Therapies N/A -56.19% -41.84%

Do analysts prefer PRTC or NBTX?

Nanobiotix has a consensus target price of $46.67, suggesting a potential upside of 81.23%. Given Nanobiotix's stronger consensus rating and higher possible upside, analysts plainly believe Nanobiotix is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nanobiotix 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher earnings and valuation, PRTC or NBTX?

Nanobiotix has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Nanobiotix $36.87M 35.35 -$27.11M N/A N/A

Is PRTC or NBTX more profitable?

Company Net Margins Return on Equity Return on Assets PureTech Health N/A N/A N/A Nanobiotix N/A N/A N/A

Do analysts prefer PRTC or SNDX?

Syndax Pharmaceuticals has a consensus price target of $41.80, suggesting a potential upside of 137.50%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Syndax Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.82

Which has preferable valuation and earnings, PRTC or SNDX?

PureTech Health has higher earnings, but lower revenue than Syndax Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Syndax Pharmaceuticals $172.35M 9.05 -$285.42M -$2.51 N/A

PureTech Health (PRTC) Competitors

$17.42 0.00 (0.00%)

As of 10/1/2026

Compare

PRTC vs. STOK, NTLA, TSHA, NBTX, and SNDX

Should you buy PureTech Health stock or one of its competitors? PureTech Health's main competitors and comparable companies include Stoke Therapeutics (STOK), Intellia Therapeutics (NTLA), Taysha Gene Therapies (TSHA), Nanobiotix (NBTX), and Syndax Pharmaceuticals (SNDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PureTech Health compare to Stoke Therapeutics?

PureTech Health (NASDAQ:PRTC) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Stoke Therapeutics has a consensus price target of $44.25, suggesting a potential upside of 72.72%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Stoke Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

PureTech Health has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. PureTech Health's return on equity of 0.00% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Stoke Therapeutics	-753.60%	-59.36%	-51.46%

0.0% of PureTech Health shares are held by institutional investors. 5.3% of PureTech Health shares are held by company insiders. Comparatively, 9.6% of Stoke Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Stoke Therapeutics has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Stoke Therapeutics	$27.59M	59.92	-$6.89M	-$3.34	N/A

In the previous week, Stoke Therapeutics had 6 more articles in the media than PureTech Health. MarketBeat recorded 6 mentions for Stoke Therapeutics and 0 mentions for PureTech Health. PureTech Health's average media sentiment score of 1.08 beat Stoke Therapeutics' score of 0.86 indicating that PureTech Health is being referred to more favorably in the media.

Company	Overall Sentiment
PureTech Health	Positive
Stoke Therapeutics	Positive

PureTech Health has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

Summary

Stoke Therapeutics beats PureTech Health on 8 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Intellia Therapeutics?

PureTech Health (NASDAQ:PRTC) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

Intellia Therapeutics has a consensus price target of $20.98, suggesting a potential upside of 71.11%. Given Intellia Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35

0.0% of PureTech Health shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 5.3% of PureTech Health shares are held by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

PureTech Health has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

PureTech Health has higher earnings, but lower revenue than Intellia Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Intellia Therapeutics	$59.51M	28.87	-$412.69M	-$3.36	N/A

PureTech Health has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -672.16%. PureTech Health's return on equity of 0.00% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

In the previous week, Intellia Therapeutics had 2 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Intellia Therapeutics and 0 mentions for PureTech Health. Intellia Therapeutics' average media sentiment score of 1.84 beat PureTech Health's score of 1.08 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PureTech Health	Positive
Intellia Therapeutics	Very Positive

Summary

Intellia Therapeutics beats PureTech Health on 9 of the 15 factors compared between the two stocks.

How does PureTech Health compare to Taysha Gene Therapies?

PureTech Health (NASDAQ:PRTC) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

PureTech Health's return on equity of 0.00% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Taysha Gene Therapies	N/A	-56.19%	-41.84%

Taysha Gene Therapies has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Taysha Gene Therapies	$9.77M	154.41	-$109M	-$0.42	N/A

PureTech Health has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market.

In the previous week, Taysha Gene Therapies had 3 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Taysha Gene Therapies and 0 mentions for PureTech Health. PureTech Health's average media sentiment score of 1.08 beat Taysha Gene Therapies' score of 0.55 indicating that PureTech Health is being referred to more favorably in the media.

Company	Overall Sentiment
PureTech Health	Positive
Taysha Gene Therapies	Positive

0.0% of PureTech Health shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 5.3% of PureTech Health shares are held by company insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Taysha Gene Therapies has a consensus target price of $12.77, indicating a potential upside of 175.79%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts plainly believe Taysha Gene Therapies is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Taysha Gene Therapies beats PureTech Health on 10 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Nanobiotix?

PureTech Health (NASDAQ:PRTC) and Nanobiotix (NASDAQ:NBTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

In the previous week, Nanobiotix had 10 more articles in the media than PureTech Health. MarketBeat recorded 10 mentions for Nanobiotix and 0 mentions for PureTech Health. PureTech Health's average media sentiment score of 1.08 beat Nanobiotix's score of -0.20 indicating that PureTech Health is being referred to more favorably in the media.

Company	Overall Sentiment
PureTech Health	Positive
Nanobiotix	Neutral

PureTech Health has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

Nanobiotix has a consensus target price of $46.67, suggesting a potential upside of 81.23%. Given Nanobiotix's stronger consensus rating and higher possible upside, analysts plainly believe Nanobiotix is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nanobiotix has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Nanobiotix	$36.87M	35.35	-$27.11M	N/A	N/A

0.0% of PureTech Health shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 5.3% of PureTech Health shares are held by insiders. Comparatively, 3.5% of Nanobiotix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Nanobiotix	N/A	N/A	N/A

Summary

Nanobiotix beats PureTech Health on 7 of the 11 factors compared between the two stocks.

How does PureTech Health compare to Syndax Pharmaceuticals?

PureTech Health (NASDAQ:PRTC) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

PureTech Health has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

In the previous week, Syndax Pharmaceuticals had 6 more articles in the media than PureTech Health. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 0 mentions for PureTech Health. PureTech Health's average media sentiment score of 1.08 beat Syndax Pharmaceuticals' score of 0.74 indicating that PureTech Health is being referred to more favorably in the media.

Company	Overall Sentiment
PureTech Health	Positive
Syndax Pharmaceuticals	Positive

Syndax Pharmaceuticals has a consensus price target of $41.80, suggesting a potential upside of 137.50%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

0.0% of PureTech Health shares are held by institutional investors. 5.3% of PureTech Health shares are held by company insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

PureTech Health has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. PureTech Health's return on equity of 0.00% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%

PureTech Health has higher earnings, but lower revenue than Syndax Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Syndax Pharmaceuticals	$172.35M	9.05	-$285.42M	-$2.51	N/A

Summary

PureTech Health beats Syndax Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get PureTech Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTC vs. The Competition

Export

Metric	PureTech Health	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$424.04M	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.64%	2.53%	16.77%
P/E Ratio	N/A	12.93	273.77	26.04
Price / Sales	91.01	1,331.86	622.72	93.41
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	1.38	16.63	10.92	6.30
Net Income	-$109.74M	-$22.67M	$3.50B	$361.43M
7 Day Performance	N/A	-3.10%	-2.07%	-1.67%
1 Month Performance	N/A	-10.70%	-6.21%	-4.51%
1 Year Performance	-8.21%	19.46%	7.45%	2.03%

PureTech Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTC PureTech Health	0.0774 of 5 stars	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100
STOK Stoke Therapeutics	3.0743 of 5 stars	$26.25 +1.4%	$44.25 +68.5%	+3.2%	$1.69B	$27.59M	N/A	170
NTLA Intellia Therapeutics	2.8518 of 5 stars	$11.97 -0.5%	$20.98 +75.2%	-40.0%	$1.68B	$59.51M	N/A	377	Gap Up
TSHA Taysha Gene Therapies	2.56 of 5 stars	$4.95 -0.9%	$12.77 +158.2%	-5.1%	$1.61B	$5.49M	N/A	99	News Coverage Positive News
NBTX Nanobiotix	2.4296 of 5 stars	$32.02 +1.7%	$46.67 +45.7%	+29.5%	$1.60B	$8.36M	N/A	97	News Coverage Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRTC) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PureTech Health (PRTC) Competitors

PRTC vs. STOK, NTLA, TSHA, NBTX, and SNDX

How does PureTech Health compare to Stoke Therapeutics?

Summary

How does PureTech Health compare to Intellia Therapeutics?

Summary

How does PureTech Health compare to Taysha Gene Therapies?

Summary

How does PureTech Health compare to Nanobiotix?

Summary

How does PureTech Health compare to Syndax Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PureTech Health (PRTC) Competitors

PRTC vs. STOK, NTLA, TSHA, NBTX, and SNDX

How does PureTech Health compare to Stoke Therapeutics?

Do analysts prefer PRTC or STOK?

Is PRTC or STOK more profitable?

Do insiders & institutionals have more ownership in PRTC or STOK?

Which has better valuation & earnings, PRTC or STOK?

Does the media prefer PRTC or STOK?

Which has more risk and volatility, PRTC or STOK?

Summary

How does PureTech Health compare to Intellia Therapeutics?

Do analysts prefer PRTC or NTLA?

Do institutionals and insiders hold more shares of PRTC or NTLA?

Which has more volatility and risk, PRTC or NTLA?

Which has stronger valuation and earnings, PRTC or NTLA?

Is PRTC or NTLA more profitable?

Does the media refer more to PRTC or NTLA?

Summary

How does PureTech Health compare to Taysha Gene Therapies?

Is PRTC or TSHA more profitable?

Which has higher valuation and earnings, PRTC or TSHA?

Which has more volatility and risk, PRTC or TSHA?

Does the media prefer PRTC or TSHA?

Do insiders and institutionals hold more shares of PRTC or TSHA?

Do analysts recommend PRTC or TSHA?

Summary

How does PureTech Health compare to Nanobiotix?

Does the media refer more to PRTC or NBTX?

Which has more risk and volatility, PRTC or NBTX?

Do analysts prefer PRTC or NBTX?

Which has higher earnings and valuation, PRTC or NBTX?

Do insiders & institutionals hold more shares of PRTC or NBTX?

Is PRTC or NBTX more profitable?

Summary

How does PureTech Health compare to Syndax Pharmaceuticals?

Which has more volatility and risk, PRTC or SNDX?

Does the media refer more to PRTC or SNDX?

Do analysts prefer PRTC or SNDX?

Do insiders and institutionals hold more shares of PRTC or SNDX?

Is PRTC or SNDX more profitable?

Which has preferable valuation and earnings, PRTC or SNDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools